Company ** |
Product |
Description |
Indication |
Type Action (Date) |
CANCER | ||||
Ligand Pharmaceuticals Inc. |
Panretin Gel (FDA-approved) |
Alitretinoin 0.1% (topical); chemically synthesized version of 9-cis-retinoic acid (derived from vitamin A) |
Treatment of dermal lesions in AIDS-related Kaposi's sarcoma |
Submitted marketing authorization application to the European Agency for the Evaluation of Medicinal Products (2/8) |
ILEX Oncology Inc. |
Intoplicine |
Synthetic anticancer agent that inhibits topoisomerase I and II; compound induces single- and double-strand DNA breaks, which lead to cancer death |
Cancer |
Added Princess Margaret Hospital at the University of Toronto as a site in Phase I trial (2/1) |
QLT Photo-Therapeutics Inc. (Canada) |
Photofrin (FDA-approved) |
Photosensitive drug (por-fimer sodium; produces toxic oxygen compound when light-activated) |
Palliative treatment of advanced lung and esophogeal cancer |
Cleared for marketing in Finland (2/25) |
CARDIOVASCULAR | ||||
Cor Therapeutics Inc. and Schering-Plough Corp. (NYSE:SGP) |
Integrilin (FDA- approved) |
Eptifibatide; small-molecule synthetic compound (derived from rattlesnake venome) that inhibits GPIIb/IIIa receptor that mediates plate let aggregation |
Prevention of myocardial infarction in patients presenting with unstable angina or non-Q wave myocardial infarction |
European Agency for the Evaluation of Medicinal Products issued positive opinion recommending approval (2/26) |
CENTRAL NERVOUS SYSTEM | ||||
Celgene Corp. and Biovail Corp. International (NYSE:BVF) |
d-MPH (d-methylphenidate hydrochloride) |
Chirally pure form of Ritalin |
Attention deficit hyperactivity disorder |
Canadian authorities approved investigational new drug application, allowing clinical trials to begin (2/16) |
Hemispherx Biopharma Inc. (AMEX:HEB) |
Ampligen |
Double-stranded synthetic RNA compound poly I:poly C12U |
Chronic fatigue syndrome (a.k.a. myalgic encephalomyelitis) |
European Union marketing application cleared first stage of regulatory review (2/4) |
Integra LifeSciences Corp. |
DuraGen Dural Graft Matrix |
Collagen matrix for the restoration of the membrane; provides a scaf-fold for the infiltration of fibroblasts and a substrate for the deposition of new collagen |
Method of dural closure dural in neurological procedures |
Received CE Mark Certification, permitting marketing in 18 European Union member states (2/4) |
NeoTherapeutics Inc. |
Neotrofin (AIT-082) |
Small-molecule compound designed to cross blood-brain barrier and enhance nerve cell function by increasing levels of neurotrophic factors |
Mild to moderate Alzheimer's disease |
Initiated Phase IIb trial in the Republic of South Africa, with additional countries to be added, pending regulatory approval (2/16) |
Neurocrine Biosciences Inc. |
NBI-34060 |
GABA receptor agonist; next-generation non-benzo-diazepine sedative hypnotic with receptor subtype selectivity |
Insomnia |
Initiated Phase Ib trials in Germany (2/1) |
Neurogen Corp. and Pfizer Inc. (NYSE:PFE) |
NGD 97-1 |
GABA (gamma aminobutyric acid) receptor agonist |
Memory disorders, including Alzheimer's disease |
Initiated Phase I trials in Europe (2/1) |
Neurogen Corp. and Wyeth-Ayerst Laboratories (subsidiary of American Home Products Corp.; (NYSE:AHP) |
ADCI |
Mild NMDA antagonist and use-dependent blocker of voltage-gated sodium channels |
Epilepsy |
Wyeth-Ayerst informed Neurogen it would not pursue further clinical testing of ADCI, which was tested in Phase Ia trials in France ( 2/1) |
INFECTION | ||||
Biota Holdings (ASX:BTA; Australia) and Glaxo Wellcomeplc (NYSE:GLX; U.K.) |
Relenza |
Zanamivir; neuraminidase inhibitor (designed and synthesized based on crystal structure of surface proteins of influenza virus); inhaled in powder form |
Treatment and prevention of influenza A and B |
Australian Drug Evaluation Committee recommended approval (2/9) |
Chiron Corp. |
Triacelluvax |
Diphtheria and tetanus toxoids and acellular pertussis vaccine |
Prevention of diphtheria, tetanus and acellular per tussis |
Cleared for marketing by the European Medicines Evaluation Agency; marketing allowed in 15 EMEA member states, except Germany (2/2) |
La Jolla Pharmaceutical Co. |
LJP 394 |
Molecule (toleragen) that binds to surface of B cells and shuts off production of antibodies to double-stranded DNA |
Nephritis in patients with systemic lupus erythematosus |
Expanded Phase II/III trial to Europe and Canada (2/25) |
Pasteur Merieux Connaught (unit of Rhone-Poulenc SA; NYSE:RP; France) |
ALVAC-HIV (vCP205) |
Recombinant canarypox expressing the glycoprotein 120 envelope protein, Gag and protease |
Prevention of HIV infection |
Initiated safety trial in Africa (2/8) |
PathoGenesis Corp. |
TOBI (FDA-approved) |
Tobramycin for inhalation |
Chronic lung infection (with Pseudomonas aeruginosa) in cystic fibrosis patients |
Cleared for marketing in Canada and Argentina (2/16) |
North American Vaccine |
DTap-IPV |
Combines Certiva, a DTaP vaccine, with injectable, inactivated polio vaccine |
Prevention of diphtheria, tetanus, acellular pertusis and polio |
Approved for marketing in Germany (2/1) |
Schering-Plough Corp. (NYSE:SGP) |
Rebetron (FDA-approved) |
Combination of Intron A (recombinant human interferon alfa-2b; injection) and Rebetol (ribavirin; synthetic nucleoside with antiviral activity; oral) |
Combination therapy for treating chronic hepatitis C virus infection in both relapse and treatment-naive adult |
Committee for Proprietary Medicinal Products of the European Agency for the Evaluation of Medicinal Products recommended approval (2/26) |
VaxGen Inc. |
AIDSVAX B/E preventive vaccine |
Bivalent vaccine consisting of recombinant copies of glycoprotein 120 from the surface of 2 types of HIV |
Prevention of HIV infection |
Thailand's Ministry of Public Health approved the start of Phase III trial (2/9) |
MISCELLANEOUS | ||||
Cortecs plc (U.K.) |
Macritonin |
Oral formulation of salmon calcitonin (a peptide hormone that inhibits bone resorption) |
Postmenopausal osteoporosis |
Completed European Phase III trial; company now in a position to collect and analyze one-year bone mineral density data and bone marker data (2/24) |
Genzyme General (division of Genzyme Corp.) |
Seprafilm Bioresorbable Membrane (FDA-approved) |
Bioresorbable membrane that prevents fibrin, unleashed as the result of surgical insult, from building the scaffolding needed for adhesions |
Reduction of incidence of adhesions following cardiac urgery |
Received CE Mark approval, permitting European Union marketing (2/10) |
SangStat Medical Corp. |
SangCya (formerlySang-35) |
Cyclosporine (oral formulation; buioequivalent to Neoral oral solution) |
Prevention of rejection in solid organ transplant recipients, as well as other immunosuppressant indications |
Cleared for marketing in the U.K. (2/4) |
NOTES: This chart is intended to provide a monthly update on the clinical and regulatory status of biotech and biotech-related products in development in countries other than the U.S., whether those products are being developed by U.S.-based or non-U.S.-based firms. ** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 16-17. |